Sirtex Medical (ASX:SRX) said today that it’s yttrium-90 resin microspheres did not extend survival significantly compared to Bayer’s sorafenib in a study of patients with hepatocellular carcinoma. Although the 459-patient trial did not meet its primary endpoint, the company reported that patients treated with its microspheres experienced less than half the number of severe, treatment-related […]
Oncology
Study: Gamida Cell’s NiCord cell graft yields fewer infections, shorter hospital stays
Gamida Cell said today that its NiCord cell graft produces fewer infections, shorter hospital stays and shorter time to engraftment compared to standard umbilical cord blood transplantation. The company’s work was published in Biology of Blood and Marrow Transplantation. “Our results indicate that rapid hematopoietic recovery from Gamida Cell’s NiCord transplantation approach is associated with clinical benefit. […]
DelMar closes $9m public offering
DelMar Pharmaceuticals (NSDQ:DMPI) closed its $9 million public offering today. Earlier this week, the company priced 2.8 million shares and warrants to purchase an aggregate of 2.1 million shares of common stock at $3.25 apiece. The offering’s warrants have an exercise price of $3.50 per share and have an term of exercise of 5 years, according to […]
Targeted drug delivery system releases chemo drug for 40 days
Researchers at Case Western Reserve University have developed a targeted drug delivery system that is triggered by the acidic environment around a tumor. The system delivers chemotherapy to the tumor for 40 days and doesn’t affect healthy tissues, according to a preclinical study published in Experimental Biology and Medicine. Traditional cancer therapy sometimes requires patients to receive […]
First European patients treated with BTG’s drug-eluting bead
BTG (LON:BTG) said today that the 1st batch of patients in the European Union were treated with its DC Bead Lumi radiopaque drug-eluting bead. Two patients were treated for hepatocellular carcinoma and 1 patient was treated for malignant colorectal cancer metastasized to the liver. The bead, which is the 1st commercially available radiopaque drug-eluting bead in […]
DelMar Pharmaceuticals prices $9m public offering
DelMar Pharmaceuticals (NSDQ:DMPI) announced pricing details of a $9 million public offering last week. The company priced 2.8 million shares and warrants to purchase an aggregate of 2.1 million shares of common stock at $3.25 apiece. The offering’s warrants have an exercise price of $3.50 per share and have an term of exercise of 5 years, […]
Study: Biodegradable nanoparticles reprogram immune cells to fight cancer
Researchers at the Fred Hutchinson Cancer Researcher Center have reportedly engineered biodegradable nanoparticles that can genetically reprogram immune cells to recognize and destroy cancer cells, without taking the immune cells out to manipulate them. The team demonstrated their idea in a proof-of-principle study published in Nature Nanotechnology. They showed that reprogrammed immune cells, or T cells, help […]
Novocure gains on additional Optune data
Shares in Novocure (NSDQ:NVCR) are on the rise again after the company today cited additional data from a pivotal trial evaluating its Optune device with temozolomide chemotherapy as a treatment for newly-diagnosed glioblastoma. Novocure’s Optune mobile device delivers low-intensity, intermediate frequency, alternating electric fields, called “tumor treating fields” or TTFields, to inhibit cancer cell replication. The […]
Adgero touts data for photodynamic drug-device combo
Adgero Biopharmaceuticals touted positive clinical data from studies of its late-stage photodynamic therapy platform for the treatment of cutaneous oncology indications, including unresectable metastatic breast cancer. The Princeton, N.J.-based company’s REM-001 therapy consists of a laser light source, a light delivery device and a photosensitizer drug. The therapy has been evaluated in 4 Phase II/III clinical […]
Keystone Nano launches clinical trial for NanoLiposome cancer therapy
Keystone Nano said today that it has begun clinical testing for its ceramide NanoLiposome cancer therapy. The Phase I trial plans to evaluate the company’s NanoLiposome as a targeted treatment for solid tumors. Ceramide is a lipid that has demonstrated efficacy in liver cancer, breast cancer, leukemia and pancreatic cancer. Preclinical evidence has shown that […]